Web Resources
If you click on any of the links below, you will be leaving us.sandostatin.com and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for those sites.
On this page:
Acromegaly Informational Websites
Acromegaly Outreach Program
http://www.acromegalysupport.com
American Association of Clinical Endocrinologists
http://www.aace.com
American Sleep Apnea Association
http://www.sleepapnea.org
The Endocrine Society
http://www.endo-society.org/
EndocrineWeb.com
http://www.endocrineweb.com
Pituitary Network Association (PNA)
http://www.pituitary.org
The Pituitary Tumor Center of Massachusetts General Hospital
http://pituitary.mgh.harvard.edu/
Society for Endocrinology
http://www.endocrinology.org/
Carcinoid Syndrome Informational Websites
American Cancer Society, Inc.
http://www.cancer.org or call 800-227-2345
Cancer Care, Inc.
http://www.cancercare.org or call 800-813-HOPE for information about support programs
Carcinoid Cancer Foundation, Inc.
http://www.carcinoid.org or call 212-722-3132
National Cancer Institute
http://www.cancer.gov
NORD (National Organization for Rare Disorders)
http://www.rarediseases.org/info/about.html
Arrange for a Sandostatin® Sales Specialist to contact your office
Important Safety Information
Carcinoid Syndrome:
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported.
The controlled clinical trials that support the marketing clearance for Sandostatin® LAR Depot did not include determination of effect on tumor size or rate of growth. Sandostatin® LAR Depot is not indicated for tumor shrinkage.
Acromegaly
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
